13F Holdings
中文EN

NXTS Nexentis Technologies Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1789192 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY-19.7%
TTM EPS YoY-31,123.8%
Revenue 3-yr CAGR-16.6%
Net income 3-yr CAGR—

Margins

Gross margin65.2%
Operating margin-2,119.7%
Net margin-3,187.1%
FCF margin—
EBITDA margin-2,114.4%

Returns

ROE-92.5%
ROA-78.9%
ROIC (approx.)-126.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets21.3%
Debt / equity0.00x
Current ratio4.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.42x
Accruals ratio-45.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—$210,000$263,000$394,004$438,141
Cost of revenue—$165,000$55,000$158,313$135,943
Gross profit—$45,000$208,000$235,691$302,198
R&D expense$179,000$369,000$1.94M$770,826$538,684
SG&A expense$5.11M$3.28M$5.58M$4.72M$4.27M
Operating income-$4.23M-$3.28M-$7.58M-$5.82M-$4.70M
Interest expense—$16——$8,339
Pretax income-$3.61M-$4.32M———
Income tax-$18,000————
Net income-$4.00M-$5.19M-$6.52M-$5.74M-$4.82M
EBITDA-$4.16M-$3.27M-$7.56M-$5.76M-$4.65M
EPS (basic)-3.54-27.74-5.4310.85-2.06
EPS (diluted)-8.61-27.74-5.4310.85-2.06
Weighted avg. shares (diluted)1.29M187,2151.20M528,7762.34M
Banking
Net interest income$0-$55,000-$66,000-$33,741—
Provision for credit losses————$116,462
Balance sheet
Cash & equivalents$3.83M$2.21M$4.48M$5.75M$6.75M
Short-term investments$239,000$307,000———
Receivables$134,000$137,000$107,000$192,597$172,630
Inventory—$21,000$122,000$81,706$22,603
Current assets$6.01M$3.45M$5.47M$6.27M$7.23M
PP&E, net$26,000$48,000$67,000$97,914$100,944
Goodwill$6.29M————
Intangibles$4.43M————
Total assets$20.41M$5.46M$7.24M$6.49M$7.60M
Current liabilities$1.43M$892,000$779,000$714,849$931,304
Short-term debt$740,000———$8,390
Long-term debt————$8,390
Total debt————$16,780
Total liabilities$4.67M$892,000$786,000$754,872$1.18M
Shareholders' equity$16.01M$4.75M$6.48M$5.85M$6.48M
Net debt————-$6.73M
Shares outstanding79,504344,7412.96M688,2722.81M
Cash flow statement
Operating cash flow-$3.81M-$3.42M-$3.23M-$5.10M-$4.11M
Capital expenditure$14,000——$51,689$67,749
Free cash flow-$3.82M——-$5.15M-$4.18M
Investing cash flow-$3.23M-$1.89M-$1.52M-$51,689-$67,749
Financing cash flow$8.86M$3.05M$3.47M$4.09M$10.73M
Depreciation & amortization$71,000$18,000$21,000$54,719$57,195
Stock-based compensation$91,000$1,000$23,000$84,171$186,438

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.